Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) (“Emerald”) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald is a vertically integrated, seed-to-sale enterprise with combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise.
Emerald’s multi-phase expansion plan is timed for massive scaling to meet demand from the legalized adult-use recreational cannabis market, which began on October 17, 2018. Emerald owns 50% of Pure Sunfarms, which consists of two adjacent 1.1 million square foot greenhouses. The first one is licensed, fully planted and estimated to exceed 75,000 kg of cannabis annually. Completion of the second greenhouse will conservatively double potential production capacity. It owns Verdélite, a Québec-based licensed producer, which is completing an 88,000 square foot indoor facility. Emerald’s wholly-owned organic operation in Metro-Vancouver comprises two 78,000 square foot state-of-the-art greenhouses and 12 acres of licensed and fully planted outdoor grow. Emerald has also entered into hemp chaff purchase agreements in 2018 and subsequent years, which will be processed for CBD extract.
Emerald’s team is highly experienced in life sciences, product development, large-scale agri-business, and marketing and is focused on developing value-added cannabis-based products with potential wellness and medical benefits.
To learn more about Emerald Health Therapeutics: